The remaining ‘triple-negative’ cases retained a five-year OS of 33-42%, roughly comparable with the survival for ALK-negative ALCL before stratification into DUSP22 and TP63 positive subgroups (58–60). The gene discussed is TP63; the disease is anaplastic large cell lymphoma.